•  
  •  
 

Subject Area

Family Medicine

Article Type

Original Study

Abstract

Objective To assess role of serum methylated septin9 (mSEPT9) in early detection of colorectal cancers (CRCs) in comparison with colonoscopy. Background mSEPT9 has been suggested as a reliable biomarker in CRC detection. We aimed to determine the diagnostic role of mSEPT9 for CRCs detection in Egyptian patients. Moreover, we compared the diagnostic efficacy of adding mSEPT9 to carcinoembryonic antigen (CEA). Patients and methods A single-center prospective study was done on 90 patients presented with signs or symptoms of CRCs. They were divided into three groups: group I (n = 45) patients with CRCs, group II patients with colorectal polyps (benign lesions) (n = 25), and group III the control group (n = 20). All patients and controls were subjected to history taking, proper examination, and investigations. Serum samples were collected for mSEPT9 and CEA. Sensitivity and specificity were calculated to evaluate the diagnostic efficacy. Results mSEPT9 achieved overall sensitivity of 84% and specificity of 78%, with an area under the curve value of 0.911. This was superior to CEA, which achieved overall sensitivity of 78% and specificity of 76%, with an area under the curve value of 0.911. The combination of mSEPT9 and CEA further improved sensitivity 100%, whereas specificity was declined to 56%. Conclusion mSEPT9 demonstrated better diagnostic ability in CRC detection compared with colonoscopy. The combination of mSEPT9 and CEA further improved diagnostic sensitivity, especially for early-stage disease, which may provide a new approach for future CRC screening.

Download

Share

COinS